Piper Jaffray reiterates a 'Buy' on Gilead Sciences (Nasdaq: GILD). Price target $63.

Piper analyst says,"U.S. HIV treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE